Linked Life Data

21546847

Source:http://linkedlifedata.com/resource/pubmed/id/21546847

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2011-8-22
pubmed:abstractText
We evaluated 70 HIV-infected pregnant women with CD4? cell count >350 cells per cubic millimeter who received zidovudine, lamivudine, and nevirapine from week 25 of gestation until 6 months after delivery and a 3-week tail of zidovudine and lamivudine at the moment of drug discontinuation. Forty days after the interruption of all drugs resistance mutations were present in 5 of 70 (7.1%) women. Two of them had the same mutation archived in baseline HIV DNA. The other 3 women had, at least once, detectable viral load and presence of mutations during treatment. Overall, the risk of developing resistance mutations in compliant women was low.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1944-7884
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
57
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
301-4
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Limited risk of drug resistance after discontinuation of antiretroviral prophylaxis for the prevention of breastfeeding transmission of HIV.
pubmed:affiliation
Department of Public Health, University of Tor Vergata, Rome, Italy.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't